中新网北京12月22日电 (记者 谢雁冰 曾玥)《国务院关于促进科技成果转化工作情况的报告》22日提请 十四届全国人大常委会审议，其中指出，中国跨区域和国际技术转移能力稳步提升。 来源：中国新闻网 报告：中国跨区域和国际技术转移能力稳步提升 报告表示，"十四五"以来，中国深化科技成果转化机制改革，完善政策支持和市场服务，科技成果转化 实现量质齐升，有效推动科技成果向现实生产力转化。 根据报告，2020年到2024年，全国技术合同成交金额从2.83万亿元(人民币，下同)增长到6.84万亿元， 增长幅度达到141.7%。新技术应用支撑传统产业优化提升，战略性新兴产业规模不断壮大，2024年规 上高技术制造业增加值较2020年增长42%，人工智能、生物科技等前沿领域正在形成新的经济增长点。 在完善科技成果转化服务体系方面，报告具体指出，跨区域和国际技术转移能力稳步提升。加快建设北 京、上海、深圳3大技术交易所，布局建设12个国家科技成果转移转化示范区。深入开展"科技援疆"等 东西部科技合作。启动建设一批"一带一路"联合实验室，优化布局国际科技合作基地。 围绕下一步工作考虑，报告提出加强原始创新和关键技术攻关，增加高 ...

□ 史修松姜东旭 在全球竞争日趋激烈的当下，科技领军企业已成为国家核心竞争力的重要载体，不仅深刻推动社会生产 生活方式革新，更在引领产业升级、激活发展动能中扮演着不可替代的角色。从发展现状来看，我国科 技领军企业逐步呈现业务领域多元、技术路径多样的发展特征，在部分细分赛道实现了突破，一批企业 在人工智能、集成电路、量子科技、生物制造等前沿领域建立起市场优势。但与全球科技领军企业相 比，在核心技术自主可控、全球市场话语权、产业链整合能力等关键维度仍存在一定差距。 要素市场化配置，增强科技领军企业成长的核心动力协同 市场机制的资源要素配置能力是科技领军企业成长的核心动力。市场机制无论是在激励科技领军企业领 导人方面，还是在支持科技领军企业全程发展壮大的融资功能上，抑或在技术迭代引发的优胜劣汰过程 中，其选择机制直接影响企业的决策。科技领军企业的市场机制是依托市场定价信号、人才市场配置效 率与产品市场竞争规则，构建以市场信号为核心的创新要素配置体系。其核心特征在于确立市场作为评 判科技领军企业优劣的标准，通过多维市场因素的协同作用，实现对行政干预的有效替代与超越。 市场机制引导创新资源向高价值领域集中，通过竞争压力 ...

（来源：工人日报） 技术创新成效显著，创新实力不断增强。我国生物制造领域专利申请量全球占比超过20%，建成一批国 家重点实验室和产业创新平台，国产高通量基因测序仪、大规模发酵罐等新型仪器装备实现产业化应 用。 产业集群优势凸显，产业结构不断优化。北京、天津等地成为生物制造创新策源地，山东、黑龙江、河 南等地形成大宗生物发酵制品制造基地，重庆、广东等地原创性成果不断涌现。"十四五"期间，我国生 物制造领域已培育形成一批年营业收入超百亿元的骨干企业，新增数十家国家级制造业单项冠军企业、 国家级专精特新"小巨人"企业，因地制宜培育首批40余家中试能力建设平台和一批优质孵化器。 本报讯（记者杨冉冉）记者从工业和信息化部获悉，"十四五"期间，我国生物制造产业蓬勃发展，在规 模、技术、集群建设等方面多点突破。"十四五"期间，我国生物制造产业规模稳步扩大，总规模达1.1 万亿元，生物发酵产品产量占全球70%以上。其中食品及添加剂、生物制药等细分领域年产值超4000亿 元，推动生物制造成为新的经济增长点。 ...

或将迎来第四家股份行AIC 今年以来，在政策的鼓励下，AIC牌照扩容节奏持续加快。截至目前，已经有8家银行系AIC正式运营。 兴业银行、中信银行，以及招商银行三家股份制银行旗下AIC自11月起已陆续揭牌运营。此外，10月 底，邮储银行也宣布获批成立AIC，但暂未正式开业。 稳步筹划相关申设工作 据悉，此前有投资者向光大银行提出："是否符合发起成立AIC的条件？"光大银行于12月22日在投资者 互动平台回应称，2025年3月，国家金融监管总局发布了《关于进一步扩大金融资产投资公司股权投资 试点的通知》（以下简称《通知》），其中提到"支持符合条件的商业银行发起设立金融资产投资公 司"，公司将持续加强与监管机构的沟通，稳步筹划相关申设工作。 同时，光大银行紧密围绕"五篇大文章"战略部署，充分发挥自身在科技金融领域的产品创新优势和综合 服务能力，不断推动股权投资与科技型企业信贷的联动，进一步提升服务实体经济的质效。 此外，展望未来，光大银行还表示，公司将在"十五五"规划的战略引导下，重点聚焦人工智能、生物制 造、新材料、高端装备、新能源与半导体等"硬科技"赛道，不断深化自身服务内涵，构建从初创投资到 产业整合的全生命 ...

Core Viewpoint - Company Jindalai is making a significant shift into the health sector by investing over 310 million yuan in two companies, marking its transition from environmental protection to a dual focus on "environment + health" [2] Investment Details - Jindalai announced an investment of 280 million yuan to acquire a 34% stake in Jici Medical, focusing on cell therapy, and an additional 30 million yuan for a 10% stake in Zhongke Hongtai, which specializes in medical robotics [2][6] - The investment in Jici Medical positions Jindalai as the second-largest shareholder, just behind the controlling shareholder [3] Financial Performance of Target Companies - Jici Medical reported revenues of 11.23 million yuan and a net profit of 1.15 million yuan for the first three quarters of 2025, but its equity remains negative at -3.15 million yuan [4] - Zhongke Hongtai's revenue for the same period was only 102,600 yuan, with a net loss of 550,770 yuan, indicating ongoing financial challenges [6] Strategic Alignment with National Policies - Both investments align with national strategic emerging industries, with Jici Medical focusing on cell therapy and Zhongke Hongtai on the trend of intelligent medical devices [6] - The "14th Five-Year Plan" identifies biomanufacturing as a new economic growth point, with stem cell technology included as a key area [6] Challenges in Core Business - Jindalai's core environmental business is under pressure, with a revenue decline of 23.5% year-on-year for the first three quarters of 2025, leading to a search for new growth avenues [8] - The company is facing a "collection battle" with multiple lawsuits, indicating difficulties in cash flow management [9][12] Cash Flow and Investment Risks - Despite current cash flow stability, with over 2.2 billion yuan in liquid assets, future investments in the new sectors may strain resources, especially given the financial status of the target companies [14] - The high-risk nature of clinical trials in cell therapy and the complex registration processes for medical robots pose additional uncertainties for Jindalai's new ventures [14][15] Technical Synergy Concerns - There is limited technical synergy between Jindalai's core wastewater treatment technology and the new health sector investments, which may hinder the company's ability to leverage its existing expertise [15]

10个核心城市包括北京、上海、天津、深圳、广州、南京、杭州、武汉、成都、合肥 我国未来产业综合发展水平整体稳步抬升，上海、北京等头部城市的优势正在进一步强化。 12月21日举行的第二届"京沪论坛"上，上海财经大学北京研究院发布的"2022-2024年城市未来产业综合 指数"显示，上海和北京持续领跑，其中上海三年内两次（2022、2024年）位列首位，指数保持高位稳 步增长；北京未来产业发展迅速，综合指数提升势头强劲。 上海市科学技术委员会主任骆大进表示，下一步，上海要抓住加快建设上海（长三角）国际科技创新中 心的契机，加强跟北京（京津冀）国际科技创新中心、粤港澳大湾区国际科技创新中心的联动发展，在 全球科技革命与产业革命深入变革之际，加快推动未来产业的发展。 十大核心城市未来产业潜力如何 《中共中央关于制定国民经济和社会发展第十五个五年规划的建议》提出，前瞻布局未来产业，探索多 元技术路线、典型应用场景、可行商业模式、市场监管规则，推动量子科技、生物制造、氢能和核聚变 能、脑机接口、具身智能、第六代移动通信等成为新的经济增长点。 上海财经大学北京研究院当天发布的《竞逐未来：中国未来产业发展趋势与核心城市潜力评 ...

转自：新华财经 一直以来，青岛将生物制造作为未来产业培育的重中之重，系统谋划、精准发力，特别是《青岛市合成 生物创新发展行动方案（2025-2027年）》的正式印发，为产业发展绘制了清晰"路线图"、制定了有 力"保障网"，推动产业发展迈出坚实步伐。以青岛琅琊台集团等为代表的骨干企业，在海洋生物资源开 发、微生物发酵技术等领域积淀深厚，发展生物制造未来产业既有基础、更有优势、更具潜力。 据了解，青岛琅琊台集团将海洋微生物技术赋能白酒酿造，打造"中国海派白酒"；依托衣康酸及其衍生 物研产销基地，坚定向合成生物制造高端领域迈进；建成海洋微藻、海洋活性肽等研发生产基地，推动 海洋生物资源的高值化开发与新质生产力转化。目前，青岛琅琊台集团已成功建设"国家认定企业技术 中心""国家级工业设计中心""中国轻工业海洋资源挖掘与产品创制工程技术中心"等八大"国字号"研发 平台，先后承担多项国家重点研发计划，并获得国家科技进步奖二等奖，在技术研发、产业转化与规模 生产等方面取得扎实成效。 青岛琅琊台集团相关负责人表示："未来，集团将坚持创新驱动，进一步深化与科研机构的产学研合 作，构建可持续的创新源泉；加速推动研发成果产业化，促 ...

Group 1: Industry Developments - The national biomanufacturing industry in China has reached a total scale of 1.1 trillion yuan, with bioproducts accounting for over 70% of global production [2] - The first high-altitude rock cave computing power cabin intelligent computing center in China has been officially launched, with a total investment of 350 million yuan and the capacity to perform 60 quintillion floating-point operations per second [3] - The "15th Five-Year Plan" proposal from Anhui Province emphasizes strengthening original innovation and tackling key core technologies, particularly in fields like integrated circuits and biomanufacturing [4] Group 2: Artificial Intelligence and Technology - Shandong Province aims for its artificial intelligence terminal industry to exceed 450 billion yuan by 2027, with a focus on producing over 100 million units and nurturing leading enterprises [5][6] - The National Medical Products Administration held a meeting to advance brain-computer interface medical devices, emphasizing safety and innovation in regulatory methods [7] - ByteDance is collaborating with hardware manufacturers like Vivo and Lenovo to integrate AI capabilities into smartphones, aiming to enhance user engagement [7] Group 3: Scientific Breakthroughs - The journal "Science" has identified the growth of global renewable energy as the top scientific breakthrough for 2025, with significant contributions from China [4] - Other breakthroughs include advancements in gene editing for rare diseases and new treatments for gonorrhea, marking significant progress in health-related research [4] Group 4: Financial and Market Insights - Guizhou Moutai retains its position as the most valuable company in China's food industry, valued at 1.9 trillion yuan, with a 1% increase from the previous year [10] - OpenAI is reportedly planning to raise up to 100 billion dollars, potentially reaching a valuation of 830 billion dollars [14] - ChatGPT mobile application has surpassed 3 billion dollars in user spending since its launch in May 2023 [15]

Core Viewpoint - Jiangxi Jindalai Environmental Protection Co., Ltd. is making significant moves towards diversification by investing in the healthcare sector, specifically in stem cell technology and medical robotics, to optimize its industrial structure and cultivate new profit growth points [2][3][21]. Investment in Healthcare - On December 19, Jindalai announced an investment of 280 million yuan in Yunnan Jici Medical Technology Co., Ltd., acquiring a 34% stake, making it the second-largest shareholder [2][21]. - On December 21, the company announced an additional investment of 30 million yuan in Beijing Zhongke Hongtai Medical Technology Co., Ltd., acquiring a 10% stake [3][21]. - Both investments target the "big health industry," with Jici Medical focusing on proprietary stem cell technology and Zhongke Hongtai excelling in medical artificial intelligence [3][21]. Rationale for Investment - Jindalai aims to respond to national calls for investment in biomanufacturing and healthcare sectors, enhancing its risk resistance and creating new profit avenues [3][21]. - The company believes that the aging population and the maturation of the industry in China present ample investment opportunities in the big health sector [3][21]. Financial Overview of Jici Medical - As of September 30, Jici Medical reported total assets of 10.01 million yuan, with revenues and net profits of 11.23 million yuan and 1.15 million yuan, respectively, for the first nine months of 2025 [6][26]. - Despite not being particularly strong financially, Jici Medical's ability to generate initial self-sustaining revenue is notable in the capital-intensive biomanufacturing sector [6][26]. Financial Overview of Zhongke Hongtai - Zhongke Hongtai reported total assets of 61.58 million yuan and a net loss of 5.51 million yuan for the first nine months of 2025 [10][31]. - The company is recognized for its innovative medical robotics and has completed 16 clinical trials for its products, which are currently in the regulatory approval process [10][31]. Jindalai's Current Position - Jindalai has a strong financial position, with a debt ratio of only 10.2% and cash reserves exceeding 1.898 billion yuan, allowing it to fund these investments entirely with its own capital [12][33]. - However, the company has experienced a decline in its main business, with a 23.5% drop in total revenue and a 30.14% decrease in net profit for the first nine months of 2025 [13][33]. Strategic Shift - The investments in Jici Medical and Zhongke Hongtai mark Jindalai's formal entry into the biomanufacturing and big health sectors, aligning with national policies that support these industries as emerging growth areas [16][36]. - The company is part of a broader trend among environmental firms diversifying into non-environmental sectors, with nearly half of the listed environmental companies exploring such opportunities [17][38].

当流量红利消退、增长神话褪色，美妆行业正被迫回答一个更本质的问题：下一轮价值评估， 究竟该建立在什么之上？ 答案，写在两份重量级的文件里。 一份文件是11月1 7日，国家药监局发布的《关于深化化妆品监管改革促进产业高质量发展的 意见》。2 4条举措中，"原料创新"被置于核心地位。另一份文件是1 2月刚出台的《化妆品企 业生产质量管理体系提升三年行动计划（2 0 2 6—2 0 2 8年）》，聚焦如何"把创新成果快速产业 化"，明确鼓励龙头企业建立"内部新原料孵化器"。 前者解决"创新怎么评"，后者回答"创新如何落地"，这一套政策组合，被业界视为对化妆品行 业科技路线的长期定调。这一套组合拳，为行业划定了未来十年的竞争坐标：科技创新，尤其 是生物制造，将成为新的准入门槛和增长引擎。 这 并 非 孤 立 事 件 。 生 物 制 造 ， 已 连 续 两 年 被 写 入 《 政 府 工 作 报 告 》 ， 定 位 为 需 要 重 点 培 育 的"未来产业"。一场从国家顶层设计到具体行业规制的浪潮已然形成。 这 意 味 着 ， 美 妆 的 故 事 ， 必 须 被 重 新 讲 述 。 它 不 再 仅 仅 是 关 于 色 ...